Methadone: You Don’t Prescribe it? You Still Need to Know About it. Karen Triandafyllis, NP Opiate Treatment Outpatient Program San Francisco General Hospital.

Slides:



Advertisements
Similar presentations
Connecting Pharmacology with Therapeutics Clive Roberts.
Advertisements

Waqas Tahir GPST2. Overview Introduction Introduction Mechanism of action Mechanism of action Therapeutic uses Therapeutic uses Pharmacokinetics Pharmacokinetics.
Alternative medicines include: Sertraline (optimum alternative as similar indications, low interaction propensity, good tolerability, generic, NICE approved)
Key dosing points: Begin a bowel regimen when opioid therapy is initiated (senna + docusate). For CHRONIC pain, use a scheduled medication regimen. ( ex:
1 Antibiotic Prevention of Acute Exacerbations of COPD Dr Farhad Abbasi Infectious Diseases Specialist.
University Hospital “Sisters of Charity” Psychiatric Clinic Vinogradska c. 29, 1000 Zagreb, Croatia Davor Moravek Addiction and psychotic.
Module 4: Interaction of. Objectives To be aware of the possible reasons why dual diagnosis occurs To be aware of the specific effects of substances on.
Sublingual Buprenorphine and Pain
Pharmacotherapy in the Elderly Paola S. Timiras May, 2007.
Pharmacotherapy in the Elderly Judy Wong
Copyright Alcohol Medical Scholars Program 1 Opioid Agonist Treatment: “Trading one substance for another?” Joseph Sakai, M.D.
Zontivity™ - vorapaxar
HIV and Psychiatric Medication Interactions
Yasar Kucukardali Professor, Internal Medicine Yeditepe University.
Rapivab™ - peramivir injection
DRUG INTERACTIONS IN EMERGENCY MEDICINE: AN OVERVIEW SCOTT LINSCOTT, MD UNIVERSITY OF UTAH SCHOOL OF MEDICINE.
SSRIs & Antidepressants
New Agents Heather Kertland, PharmD.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 11 Drug Therapy in Geriatric Patients.
The Role of Clinical Pharmacists in Outpatient Psychiatric Clinics Mary A. Gutierrez, Pharm.D., BCPP Associate Professor of Clinical Pharmacy University.
Seizure Threshold and Psychoactive Drugs Sue Henderson.
BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS Module III – Buprenorphine 101.
Medication Assisted Therapy for Opioid Addiction: Methadone and Buprenorphine Andrew J. Saxon, M.D. Veterans Affairs Puget Sound Health Care System and.
Strategies to Switch Antidepressants Brittany Parmentier, PharmD PGY2 Behavioral Care Resident Butler University/Community Health Network This speaker.
RELATIVE TOXICITY OF CITALOPRAM AND OTHER SSRIs IN OVERDOSE GK Isbister 1,2, IM Whyte 1,2, AH Dawson 1,2 1 Department of Clinical Toxicology, Newcastle.
Psychobiology Research Group Pharmacokinetics and Phamacogenetics Hamish McAllister-Williams PhD, MD, FRCPsych Reader in Clinical Psychopharmacology Newcastle.
For Pain or Not for Pain: Methadone Madness
1 Clinical Toxicology & Pharmacology Newcastle Mater Misericordiae Hospital Risks of Psychotropics.
Problems of Polypharmacy
ZOLPIDEM Dr Anne-Louise Swain Clinical Forensic Medical Officer
Sprout Pharmaceuticals Inc. FDA Approval Date: August 18, 2015
Psychiatric Medications: Interactions Chitra Malur MD Asst. Chief of Service Dept. of Psychiatry UMDNJ.
Clinical Management Course: Medical Complications of Alcoholism Peter R. Martin, M.D. Professor of Psychiatry and Pharmacology.
Manufacturer: Amgen Inc FDA Approval Date: August 27, 2015
DRUG TREATMENT OF HEART FAILURE IN PATIENTS WITH CHRONIC RENAL DISEASE Presented by Ri.
Foundation Knowledge and Skills
METABOLISME DEPARTMENT OF PHARMACOLOGY AND THERAPEUTIC UNIVERSITAS SUMATERA UTARA dr. Yunita Sari Pane.
Department of Pharmacy, Ditmanson Medical Foundation Chia-Yi Christian Hospital Suspect Moxifloxacin Induced Torsades de Pointes: A case report Ya-Wen.
Manufacturer: Relypsa Inc. FDA Approval Date: October 21, 2015
Drug interactions in dementia Stephen Bleakley Locality Lead Pharmacist November 2010
ALLIE PUNKE PHARMACOKINETICS: PSYCHOTROPIC DRUGS.
Medication Assisted Treatment for Opioid Use Disorders
Module 1–1 1TIP45 Training Curriculum U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for.
Prepared by Dr. Ramin Safakish, MD, FRCPC – March 2016.
Flibanserin โดย เภสัชกรหญิงคริสติน่า ลี้สุรพลานนท์
Current Concepts in Pain Management
Nuplazid™ - Pimavanserin
Pharmacokinetics: psychotropic drugs
William Eggleston, PharmD1, Nicholas Nacca, MD3, and Jeanna M
Pharmacokinetics: HIV Drugs
Drug Therapy in Geriatric Patients
Pharmacokinetics: HIV Drugs
Drug Elimination Drug elimination consists of 2 processes
Analysis of Safety and Efficacy of Dexmedetomidine as Adjunctive Therapy for Alcohol Withdrawal in ICU Vincent Rizzo MD MBA FACP Ricardo Lopez MD FCCP.
Anticonvulsants: Valproic acid
Drugs Affecting the Central Nervous System
School of Pharmacy, University of Nizwa
Pharmcokinetics Allie punke.
School of Pharmacy, University of Nizwa
THE MODERN MANAGEMENT OF PAIN IN PALLIATIVE MEDICINE
Antipsychotics: chemistry and pharmacokinetics
Sertraline In this section we’ll discuss the most relevant aspects of sertraline.
Lurasidone Flavio Guzmán, MD.
Citalopram and Escitalopram
Tricyclic and Tetracyclic Antidepressants Adverse Effects and Pharmacokinetics In this presentation we discuss adverse effects and pharmacokinetics of.
Relapses or deteriorates
Implications for safe medication prescribing in older adults
Case 1 – 17 yo white female 2 year history of using opioids – prescription post minor surgery, continued use post prescription (non-medical sources) –
Tapering and Discontinuing Chronic Opioid Therapy
Presentation transcript:

Methadone: You Don’t Prescribe it? You Still Need to Know About it. Karen Triandafyllis, NP Opiate Treatment Outpatient Program San Francisco General Hospital April 22, 2010

Methadone has many interactions with both prescribed medications and substances of abuse These interactions, in turn, can significantly impact patient outcomes Medical Psychiatric Substance Abuse

Case Study #1 48-year old male with Opioid and Cocaine Dependence, HIV, Hep C+, and Depressive disorder On Methadone 70mg daily, no illicit opioid use x 6 mos, continues to use crack cocaine 3-4x/wk On Sertraline 100mg qbedtime for depression PCP wants to start pt on HIV meds. Some concerns re possible adherence, but thinks stable enough. Prescribes Atripla 1 tab daily Pt misses initial f/u appt with PCP, returns 4 wks later. States he relapsed on heroin and has been off all his medications, except for Methadone, for the past 2 wks What do you do to help him?

Case Study #2 35-year old female with Opioid and Methamphetamine Dependence, Hep C+, HTN, OCD and Anxiety d/o NOS On Methadone 50mg daily and HCTZ 25mg daily Enters residential tx, does well, stops using any illicit drugs, engages in psychiatric care and is started on Fluvoxamine 100mg daily and Clonazepam 0.5mg BID You receive a call from her program stating that she has been nodding off in groups and they are concerned she is abusing her benzos What can you do to help her?

Methadone Pharmacology Opiate agonist High systemic bioavailability (90%) Peak plasma levels at 2-4 hours Long T ½ allows convenient dosing, but T ½ is quite variable Relatively lipid soluble Duration of analgesia << expected with T ½

Methadone Pharmacology (cont’d) Stored and accumulates in tissues (esp. liver) which extend the apparent T ½ 90% protein bound (not eliminated by dialysis) Biotransformation by P450 (3A4 and 2D6 mainly) Cleared by GI tract in patients with significant renal disease

Methadone Safety: Black Box Warnings

QTc Prolongation and Torsade 2009 Clinical Guidelines for QTc Interval Screening in Methadone Treatment: Consensus Recommendations Disclosure: Clinicians should inform patients of arrhythmia risk when they prescribe methadone. Clinical History: Clinicians should ask patients about any history of structural heart disease, arrhythmia, and syncope. Screening: Obtain a pretreatment electrocardiogram for all patients to measure the QTc interval and then a follow-up electrocardiogram within 30 days and annually. Additional electrocardiography is recommended if the methadone dosage exceeds 100 mg/d or if patients have unexplained syncope or seizures. Risk Stratification: If the QTc interval is greater than 450 ms but less than 500 ms, discuss potential risks and benefits with patients and monitor them more frequently. If the QTc interval exceeds 500 ms, consider discontinuing or reducing the methadone dose; eliminating contributing factors, such as drugs that promote hypokalemia; or using an alternative therapy. Drug Interactions: Clinicians should be aware of interactions between methadone and other drugs that possess QT interval–prolonging properties or slow the elimination of methadone. Krantz et al (2009). Ann Intern Med. 2009;150:

QTc Prolongation and Torsade (cont’d) Major risk factors include Electrolyte abnormalities (hypomagnesemia, hypokalemia, hypocalcemia) Hepatic dysfunction Other QT prolonging medications

Methadone-Drug Interactions CYP inhibitors Slow Methadone metabolism, raise serum methadone levels, extend duration of its effects, possible cause Methadone-related toxicity (e.g., oversedation, respiratory depression, prolonged QTc) Overmedication reactions develop within a few days after concurrent drug administration CYP inducers Accelerate Methadone breakdown, abbreviate duration of Methadone effects, lower serum methadone levels, possibly precipitate withdrawal May take a week or much longer to emerge, producing withdrawal sx Not all interactions are related to altered drug metabolism Additive effects of Methadone with other CNS depressants, for example, causing hypotension, sedation, respiratory depression or coma Other QTc prolonging medications Methadone can also increase or decrease some concomitant drug levels, leading to toxicity or lack of efficacy Also consider potential effects when discontinuing medications

Risks of Reduced Serum Methadone Levels Potential relapse to illicit opioids Non-adherence to prescribed medications

Prescribing Medications that Interact with Methadone Use alternative, non-interacting drugs if possible Adjust concomitant drug as appropriate if Methadone affects its levels Advise pts in advance of physical symptoms of overmedication or withdrawal that may occur Encourage pts to let their Methadone Clinic know about initiation or discontinuation of interacting medications Inform Methadone Clinic about changes For W93 pts, call and ask for the NP on call

Methadone-Drug Interactions: HIV medications DrugEffects Didanosine (ddl)Significant ↓ in ddl concentration Stavudine (d4T)Significant ↓ in d4T concentration Zidovudine (AZT)AZT concentration increased 40% Abacavir (ABC) ↓ Methadone level; ↓ ABC peak concentration Efavirenz ↓ Methadone level, withdrawal common Lopinavir+Ritonavir ↓ Methadone level, withdrawal common Darunavir ↓ Methadone level, withdrawal may occur Nevirapine ↓ Methadone level, may precipitate withdrawal

Methadone-Drug Interactions: Psychotropic medications DrugEffects BenzodiazepinesAdditive CNS depression MAOIsContraindicated due to potential adverse reactions TCAs (amitriptyline, desipramine, imipramine, nortriptyline) ↑ TCA toxicity (desipramine level doubles), proarrhythmic effects SSRIs/SNRIs (fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine) fluvoxamine: Potentially dangerous ↑ in Methadone levels. Moderate Methadone ↑ : fluoxetine Mild Methadone ↑ : paroxetine, venlafaxine QTc: fluoxetine, sertraline, venlafaxine Antipsychotics (haloperidol, quetiapine, ziprasidone) QTc prolongation Quetiapine: ↑ Methadone levels CarbamazepineStrong CYP3A4 induction, opioid withdrawal common

Methadone-Drug Interactions: Other medications DrugEffects BarbituatesParticularly phenobarbital, sharp ↓ in Methadone levels and opioid withdrawal Phenytoin and CarbamazepineSharp ↓ in Methadone levels RifampinSevere opioid withdrawal Fluconazole (possible other azoles) ↑ Methadone levels Macrolides (Erythromycin, Clarithromycin) ↑ Methadone levels St. John’s WortSignificant ↓ in Methadone levels (47% in one study) Grapefruit juice ↑ Methadone levels OmeprazoleMay inhibit Methadone absorption CimetidineCYP450 enzyme inhibitor

Methadone-Drug Interactions: Substances of Abuse ETOH and Sedatives: additive effects, risk for overdose Cocaine: accelerates Methadone elimination Methamphetamine: not studied in human pharmacokinetics studies Tobacco: mixed reports, most indicate reduced effectiveness of Methadone

Case Study #1 48-year old male with Opioid and Cocaine Dependence, HIV, Hep C+, and Depressive disorder On Methadone 70mg daily, no illicit opioid use x 6 mos, continues to use crack cocaine 3-4x/wk On Sertraline 100mg qbedtime for depression PCP wants to start pt on HIV meds. Some concerns re possible adherence, but thinks stable enough. Prescribes Atripla 1 tab daily Pt misses initial f/u appt with PCP, returns 4 wks later. States he relapsed on heroin and has been off all his medications, except for Methadone, for the past 2 wks What do you do to help him?

Case Study #2 35-year old female with Opioid and Methamphetamine Dependence, Hep C+, HTN, OCD and Anxiety d/o NOS On Methadone 50mg daily and HCTZ 25mg daily Enters residential tx, does well, stops using any illicit drugs, engages in psychiatric care and is started on Fluvoxamine 100mg daily and Clonazepam 0.5mg BID You receive a call from her program stating that she has been nodding off in groups and they are concerned she is abusing her benzos What can you do to help her?

Ward 93 Contact Information Referrals Referral forms available at most clinics, ED, Wound Clinic, and Urgent Care Fax referral form to Bryan Jackson at or call at Most pts admitted to 30-day or 90-day detox Direct admission to MMTP for pregnant pts or Forensic AIDS Program (FAP) pts To discuss medical concerns and coordinate care, phone and ask for the NP on call

Questions?